BHVN:NYE-Biohaven Pharmaceutical Holding Co Ltd (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 38.25

Change

-0.18 (-0.47)%

Market Cap

USD 3.93B

Volume

0.72M

Analyst Target

USD 83.60
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut. Biohaven Ltd. was formerly a subsidiary of Biohaven Pharmaceutical Holding Company Ltd.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-02-10 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
RCUS Arcus Biosciences Inc

-0.10 (-0.80%)

USD 1.19B
NUVB Nuvation Bio Inc

-0.10 (-4.20%)

USD 0.78B
DNA Ginkgo Bioworks Holdings

-0.73 (-5.12%)

USD 0.62B
CYBN Cybin Inc

+0.37 (+4.11%)

USD 0.20B
PLX Protalix Biotherapeutics Inc

-0.11 (-4.14%)

USD 0.20B
ADCT ADC Therapeutics SA

-0.04 (-2.65%)

USD 0.16B
ANRO Alto Neuroscience, Inc.

-0.26 (-7.12%)

USD 0.12B
ARMP Armata Pharmaceuticals Inc

-0.06 (-2.88%)

USD 0.07B
OSTX OS Therapies Incorporated

-0.06 (-3.06%)

USD 0.07B
ANVS Annovis Bio Inc

-0.20 (-6.80%)

USD 0.06B

ETFs Containing BHVN

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 2.41% 66% D+ 51% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 2.41% 66% D+ 51% F
Trailing 12 Months  
Capital Gain -21.47% 70% C- 10% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -21.47% 70% C- 9% A-
Trailing 5 Years  
Capital Gain -15.23% 91% A- 32% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -15.23% 78% C+ 18% F
Average Annual (5 Year Horizon)  
Capital Gain 41.21% 86% B+ 91% A-
Dividend Return 41.21% 86% B+ 91% A-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 95.03% 43% F 9% A-
Risk Adjusted Return 43.37% 97% N/A 57% F
Market Capitalization 3.93B 100% F 75% C

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.